Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Merck quits two trials
View:
Post by O12009 on Dec 17, 2024 1:34pm

Merck quits two trials

Merck calls quits on two immunotherapies for cancer

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.

Merck & Co. has long been dominant in cancer immunotherapy, with its drug Keytruda earning 40 approvals en route to becoming the world’s best-selling medicine. But the New Jersey-based drugmaker has had difficulty finding a successor, and a Monday announcement is the latest evidence.

In a statement, Merck said it will end development of two experimental cancer drugs that are currently in late-stage testing. One, called vibostolimab, is aimed at a target called TIGIT. The other, favezelimab, homes in a protein named LAG-3. Both were being evaluated in combinations with Keytruda, and have been touted by Merck as a way to extend Keytruda’s market advantage beyond 2028, when its main U.S. patent will expire.

The two drug targets have been central to drugmakers’ efforts to find new cancer medicines that can boost the benefit of immunotherapies like Keytruda. LAG-3, for example, is the target of a drug Bristol Myers Squibb has brought to market for melanoma, as well as experimental therapies from Regeneron and others. Several drugmakers, among them Roche, GSK and Gilead Sciences, have invested heavily in TIGIT therapies, so far with mostly disappointing results.

According to Merck, emerging findings from trials of vibostolimab and favezelimab led it to scrap each. Following an interim check of two Phase 3 lung cancer studies, trial monitors found the Keytruda-vibostolimab combination met a pre-specified “futility criteria,” meaning patients who’d received it were unlikely to live longer than those treated with Keytruda alone. Rates of immune-related side effects were higher with the combination as well.

Merck separately chose to terminate favezelimab development after reviewing data from all of its trials and concluding it should prioritize other medicines instead.

“Following a careful analysis of the data, the decision has been made to discontinue development of these candidates to prioritize other ongoing programs,” Marjorie Green, head of oncology global clinical development at Merck Research Laboratories, said in a statement. “We continue to pursue the most promising science with a focus on agents with the greatest potential to improve outcomes for more patients with cancer.”

In a note to clients, Leerink Partners analyst Daina Graybosch noted how the vibostolimab combination’s failure was likely the result of “toxicity and difficulty in maintaining patients on treatment through toxicity.” She likened Merck’s decision to discard that drug and favezelimab as “ripping off the Band-Aid,” as investor expectations had already cooled and Merck can now shift its attention to launching a form of Keytruda injected under the skin.
 

They would be smart to JV with Theralase and try are drug in a combo.

Comment by CancerSlayer on Dec 17, 2024 1:52pm
I'm waiting for Keytruda to finally marry/partner with its better half...
Comment by Alamir1111 on Dec 17, 2024 2:02pm
I would bless that marriage. 
Comment by bmk211 on Dec 17, 2024 2:42pm
At $100 per share
Comment by kammen83 on Dec 17, 2024 3:04pm
Should i buy more? Already have 125.500.
Comment by O12009 on Dec 17, 2024 3:15pm
If you pay taxes in Canada you should have your tax free savings account full of TLT . At today's price you should be able to buy 300000 shares if you haven't use any of what your allowed to put in.  For me it is $80000 /.26= 300000 shares.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250